UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

Proceedings of the National Academy of Sciences - PNAS, 2010-07, Vol.107 (28), p.12469-12474

2010

Volltextzugriff (PDF)

Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors

Cancer research (Chicago, Ill.), 2011-03, Vol.71 (5), p.1573-1583

2011

Volltextzugriff (PDF)

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

Clinical cancer research, 2011-07, Vol.17 (13), p.4378-4388

2011

Volltextzugriff (PDF)

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors

Cancer research (Chicago, Ill.), 2008-10, Vol.68 (20), p.8322-8332

2008

Volltextzugriff (PDF)

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Blood, 2012-01, Vol.119 (2), p.476-487

2012

Volltextzugriff (PDF)

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.532-541

2007

Volltextzugriff (PDF)

Targeting TORC1/2 Enhances Sensitivity to EGFR Inhibitors in Head and Neck Cancer Preclinical Models

Neoplasia (New York, N.Y.), 2012-11, Vol.14 (11), p.1005-1014

2012

Volltextzugriff (PDF)

When chronic and rare disease worlds converge

Nature reviews. Drug discovery, 2024-09, Vol.23 (9), p.654-655

Mullard, Asher

2024

Volltextzugriff (PDF)

ATR Kinase Activity Regulates the Intranuclear Translocation of ATR and RPA following Ionizing Radiation

Current biology, 2003-06, Vol.13 (12), p.1047-1051

2003

Volltextzugriff (PDF)

Plasma‐Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States

Journal of bone and mineral research, 2022-03, Vol.37 (3), p.475-483

2022

Volltextzugriff (PDF)

An ensemble approach to accurately detect somatic mutations using SomaticSeq

Genome Biology, 2015-09, Vol.16 (1), p.197, Article 197

2015

Volltextzugriff (PDF)

Evaluation of analyte sensitivity and cross-reactivity to complement component 5 (C5) in three C5a and two SC5b-9 immunoassays

Molecular immunology, 2018-10, Vol.102, p.226-227

2018

Volltextzugriff (PDF)

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

British journal of cancer, 2016-04, Vol.114 (8), p.889-896

2016

Volltextzugriff (PDF)

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Clinical & experimental metastasis, 2008, Vol.25 (6), p.685-693

2008

Volltextzugriff (PDF)

Activation of the JC Virus Tat-Responsive Transcriptional Control Element by Association of the Tat Protein of Human Immunodeficiency Virus 1 with Cellular Protein Purα

Proceedings of the National Academy of Sciences - PNAS, 1996-11, Vol.93 (24), p.14112-14117

1996

Volltextzugriff (PDF)

Abstract A2: Selective inhibition of mTORC1/mTORC2 sensitizes prostate cancer cells to the effects of AR or IGF-1R/IR antagonists, providing an approach to overcome intrinsic mechanisms of resistance

Clinical cancer research, 2012-05, Vol.18 (10_Supplement), p.A2-A2

2012

Volltextzugriff (PDF)

Abstract 1632: Co-targeting mTOR and IGF-1R/IR results in synergistic activity against a broad array of tumor cell lines, independent of KRAS mutation status

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.1632-1632

2010

Volltextzugriff (PDF)

Abstract B1: Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth

Clinical cancer research, 2012-05, Vol.18 (10_Supplement), p.B1-B1

2012

Volltextzugriff (PDF)

Targeting TORC1/2 Enhances Sensitivity to EGFR Inhibitors in Head and Neck Cancer Preclinical Models1

Neoplasia (New York, N.Y.), 2012-11, Vol.14 (11), p.1005-1014

2012

Volltextzugriff (PDF)

Abstract 2403: Proteomic profiling of signaling pathways in LKB1 deficient non-small cell lung cancers (NSCLC) identifies novel therapeutic targets including IGF1R pathway

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2403-2403

2013

Volltextzugriff (PDF)

Abstract 4463: OSI-027, a dual mTORC1/mTORC2 inhibitor, induces autophagy in cancer cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4463-4463

2011

Volltextzugriff (PDF)

Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

Blood, 2010-11, Vol.116 (21), p.772-772

2010

Volltextzugriff (PDF)

OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy

Blood, 2010-11, Vol.116 (21), p.970-970

2010

Volltextzugriff (PDF)

Ras-induced colony formation and anchorage-independent growth inhibited by elevated expression of Purα in NIH3T3 cells

Journal of cellular biochemistry, 2001, Vol.81 (4), p.621-638

2001

Volltextzugriff (PDF)

Functional interaction of Purα with the Cdk2 moiety of cyclin A/Cdk2

Biochemical and biophysical research communications, 2005-03, Vol.328 (4), p.851-857

2005

Volltextzugriff (PDF)

1 – 25 von 328

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(312)
Mit Volltextzugriff
(249)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(328)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Targeting TORC1/2 Enhances Sensitivity to EGFR Inhibitors in Head and Neck Cancer Preclinical Models

When chronic and rare disease worlds converge

ATR Kinase Activity Regulates the Intranuclear Translocation of ATR and RPA following Ionizing Radiation

Plasma‐Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States

An ensemble approach to accurately detect somatic mutations using SomaticSeq

Evaluation of analyte sensitivity and cross-reactivity to complement component 5 (C5) in three C5a and two SC5b-9 immunoassays

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Activation of the JC Virus Tat-Responsive Transcriptional Control Element by Association of the Tat Protein of Human Immunodeficiency Virus 1 with Cellular Protein Purα

Abstract A2: Selective inhibition of mTORC1/mTORC2 sensitizes prostate cancer cells to the effects of AR or IGF-1R/IR antagonists, providing an approach to overcome intrinsic mechanisms of resistance

Abstract 1632: Co-targeting mTOR and IGF-1R/IR results in synergistic activity against a broad array of tumor cell lines, independent of KRAS mutation status

Abstract B1: Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth

Targeting TORC1/2 Enhances Sensitivity to EGFR Inhibitors in Head and Neck Cancer Preclinical Models1

Abstract 2403: Proteomic profiling of signaling pathways in LKB1 deficient non-small cell lung cancers (NSCLC) identifies novel therapeutic targets including IGF1R pathway

Abstract 4463: OSI-027, a dual mTORC1/mTORC2 inhibitor, induces autophagy in cancer cells

Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy

Ras-induced colony formation and anchorage-independent growth inhibited by elevated expression of Purα in NIH3T3 cells

Functional interaction of Purα with the Cdk2 moiety of cyclin A/Cdk2

Suchergebnisse filtern